Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Izzy who wrote (2451)	10/22/1997 1:36:00 AM
From: JOHN W.	of 6136

<does anyone know what the estimated European sales will be?> L. Moss addressed Europe today: Subject: Re: Viracept revenues now exceed Merck's Crixivan's in U.S. market Date: Tue, Oct 21, 1997 15:41 EDT From: LMoss Message-id: <19971021194100.PAA06282@ladder01.news.aol.com> I think that the European approval process has moved beyond the CPMP, which I suspect did what it had to do at its previous meeting. The most likely reason for the move upward in stock price, in my opinion, is simply that AGPH is an extremely undervalued stock. My estimate of current intrinsic value is $148/share. (For readers with eagle eyes, this is not a typographical error. My previous estimate of $147/share was based on a slighly longer discount period. The current value will increase about $1/week as the discount rate is applied to a shorter period.) LMoss

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next